risperidone has been researched along with Dementia in 183 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the effects of galantamine and risperidone on neuropsychiatric symptoms in dementia (NPSD) and global function." | 9.19 | Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial. ( Eriksdotter, M; Freund-Levi, Y; Jedenius, E; Lärksäter, M; Tysen-Bäckström, AC; Wahlund, LO, 2014) |
| "To examine the effects of galantamine and risperidone on agitation in patients with dementia." | 9.19 | Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study. ( Aarsland, D; Auestad, B; Bloniecki, V; Freund-Levi, Y; Lärksäter, M; Tysen Bäckström, AC, 2014) |
| "When comparing treatment effects on individual symptoms frequently occurring in patients with dementia, risperidone significantly improved symptoms of agitation, wandering, diurnal rhythm disturbance and anxieties, among other symptoms, compared with haloperidol." | 9.12 | Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia. ( Choi, SK; Greenspan, AJ; Suh, GH, 2006) |
| "In this study we directly compared the efficacy and tolerability of the atypical antipsychotics quetiapine and risperidone in elderly patients with dementia and symptoms of disturbed perception, thought content, mood or behaviour (behavioural and psychological symptoms of dementia-BPSD)." | 9.12 | Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function. ( Haushofer, M; Pfolz, H; Rainer, M; Struhal, C; Wick, W, 2007) |
| "To compare citalopram and risperidone for the treatment of psychotic symptoms and agitation associated with dementia, with a priori hypotheses that risperidone would be more efficacious for psychosis and citalopram for agitation." | 9.12 | A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. ( Blakesley, RE; Houck, PR; Huber, KA; Mazumdar, S; Mulsant, BH; Pollock, BG; Rosen, J, 2007) |
| "Large randomized controlled trials have shown that risperidone reduces the frequency and severity of behavioral and psychological symptoms of dementia (BPSD) in patients with dementia." | 9.11 | Efficacy of risperidone for treating patients with behavioral and psychological symptoms of dementia. ( Wancata, J, 2004) |
| "To compare risperidone treatment with placebo for the burden to nursing staff of older nursing-home residents with dementia." | 9.11 | The effect of risperidone on nursing burden associated with caring for patients with dementia. ( Brodaty, H; Ciesla, G; Frank, L; Kleinman, L; Rupnow, MF, 2004) |
| "To examine the effect of risperidone on specific behavioral and psychological symptoms of dementia (BPSD)." | 9.11 | Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. ( Brodaty, H; Davidson, M; De Deyn, PP; Greenspan, A; Katz, IR; Rabinowitz, J, 2004) |
| "Eighty-six patients with probable Alzheimer's disease, vascular dementia, or mixed-etiology dementia (DSM-IV criteria) were randomly assigned to treatment with olanzapine or risperidone." | 9.11 | Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. ( Bastean, JN; Bossie, CA; Gharabawi, GM; Greenspan, AJ; Mao, L; Martinez, RA; Mulsant, BH; Pollock, BG; Tune, LE, 2004) |
| " Dementia patients with behavioral and psychological symptoms received risperidone for 3 months." | 9.11 | Open-label, observational study of the effects of risperidone on the behavioral and psychological symptoms of dementia and caregiver stress in the community setting. ( Antonio Burón, J; Arriola, E; Gallego, R; Ignacio Diago, J, 2005) |
| "Risperidone significantly improves behavioral and psychological symptoms of dementia (BPSD), including aggression, agitation and psychosis, as shown by randomized, placebo-controlled trials." | 9.11 | Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice. ( Kurz, A; Schmitt, A; Schwalen S, S, 2005) |
| "In a double-blind parallel study allowing dose titration over 14 days, 39 agitated persons with DSM-IV dementia who were residing in long-term care facilities were administered olanzapine (N = 20) or risperidone (N = 19) as acute treatment." | 9.10 | A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. ( Fontaine, CS; Hynan, LS; Koch, K; Martin-Cook, K; Svetlik, D; Weiner, MF, 2003) |
| "To compare the effects of risperidone and olanzapine on cognition in elderly patients with dementia and psychosis, and to compare the side effects of these drugs." | 9.10 | Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. ( Arndt, S; Ekstam-Smith, K; Ellingrod, VL; Kutscher, E; Schultz, SK; Turvey, C, 2002) |
| "65 patients suffering from AD, 10 from vascular dementia, and 15 from both were randomized to open label rivastigmine and risperidone, alone or in combination, for 20 weeks." | 9.10 | A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. ( Anand, R; Cicin-Sain, A; Hartman, R; Korczyn, AD; Rotmensch, HH; Weiser, M, 2002) |
| "We report the findings from the first large, double-blind, placebo-controlled study conducted to evaluate the efficacy and safety of risperidone in the treatment of psychotic and behavioral symptoms in institutionalized elderly patients with dementia." | 9.09 | Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. ( Brecher, M; Clyde, C; Jeste, DV; Katz, IR; Mintzer, JE; Napolitano, J, 1999) |
| "The authors studied the incidence of tardive dyskinesia in elderly institutionalized patients with dementia being treated with risperidone." | 9.09 | Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. ( Jeste, DV; Kane, JM; Martinez, RA; Napolitano, J; Okamoto, A, 2000) |
| "Risperidone was used to treat 11 elderly hospitalized patients between 61 and 79 years of age who manifested signs of psychoses related to schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia." | 9.08 | Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. ( Abaza, A; Araujo, L; Brenner, R; Madhusoodanan, S, 1995) |
| "The efficacy and safety of risperidone, haloperidol, and thioridazine for treating dementia-associated behavioral disturbances were evaluated in a retrospective study of 186 patients aged 65 years or older with DSM-III-R or DSM-IV diagnoses of Alzheimer's dementia, senile dementia NOS, or organic brain syndrome." | 9.08 | Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances. ( Frenchman, IB; Prince, T, 1997) |
| "The authors describe a series of 22 patients with dementia and behavioral disturbances, including agitation, aggression, delusions, and hallucinations, who were treated with risperidone." | 9.08 | Risperidone for the treatment of behavioral disturbances in dementia: a case series. ( Campbell, B; Flynn, M; Herrmann, N; Rabheru, K; Rivard, MF; Ward, C, 1998) |
| "Data from all double-blind randomised controlled trials of risperidone in dementia patients (risperidone n = 1009, placebo n = 712) were included." | 8.93 | Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients. ( Berlin, JA; Coppola, D; Costafreda, SG; Hough, D; Howard, R; Karcher, K, 2016) |
| "This study is a meta-analysis of patients with psychosis of AD from four large placebo-controlled clinical trials of risperidone in dementia." | 8.84 | The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. ( Brodaty, H; de Deyn, PP; Greenspan, A; Katz, I; Mintzer, J; Zhu, Y, 2007) |
| "Post-hoc analysis by the pharmaceutical company Eli Lilly of 5 randomised clinical trials concerning the efficacy ofolanzapine in patients with dementia, has shown that patients taking olanzapine have a risk of experiencing a cerebrovascular accident which is 3 times higher than patients taking placebo." | 8.82 | [Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia]. ( Jansen, PA; van Marum, RJ, 2005) |
| "Risperidone offers physicians the unique combination of extensive, published clinical experience and a good safety profile for treating patients with dementia who have symptoms of aggression, agitation, and psychosis." | 8.81 | Risperidone for the treatment of behavioral and psychological symptoms of dementia. ( Tune, LE, 2001) |
| "Currently available research on the use of risperidone to manage agitation in patients with dementia is discussed." | 8.80 | Risperidone for control of agitation in dementia patients. ( Falsetti, AE, 2000) |
| "The efficacy of risperidone has been demonstrated in the treatment of the behavioural and psychological symptoms associated with dementia in the elderly." | 8.80 | Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia. ( Bhana, N; Spencer, CM, 2000) |
| "The aim of this study was to compare the efficacy and side-effect profile of the typical antipsychotic haloperidol with that of the atypical antipsychotics risperidone, olanzapine, and aripiprazole in the management of delirium." | 7.81 | Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects. ( Boettger, S; Breitbart, W; Jenewein, J, 2015) |
| "This study was intended to compare the consistency of risperidone exposure in patients who have dementia and behavioral disturbances treated in a psychiatric hospital versus a community care setting." | 7.73 | Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances. ( Bies, RR; Huber, KA; Kirshner, MA; Mulsant, BH; Pollock, BG; Rosen, J; Wilson, NL, 2005) |
| "Following changes in the safety information on the use of risperidone and olanzapine in elderly patients with dementia, data from prescription-event monitoring (PEM) studies of risperidone, quetiapine and olanzapine were examined." | 7.73 | Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. ( Harris, S; Layton, D; Shakir, SA; Wilton, LV, 2005) |
| "In March 2004, the UK Committee of Safety of Medicines (CSM) informed clinicians that risperidone and olanzapine should not be used to treat behavioural and psychological symptoms of dementia (BPSD) because of increased risk of strokes with both drugs and increased risk of mortality with olanzapine." | 7.73 | Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued? ( Shah, A, 2006) |
| " Three nursing-home residents who suffered from multiple somatic disorders and dementia, two men aged 78 and 76 years respectively and a woman aged 72 years, developed neuroleptic malignant syndrome following the use of risperidone." | 7.72 | [Neuroleptic malignant syndrome in users of risperidone]. ( de Jonghe-Rouleau, AP; Gerritsen, AA; Stienstra-Liem, LH, 2004) |
| " We conducted an 8-week, rater-blinded, randomized trial, administering flexibly dosed risperidone, yokukansan, or fluvoxamine." | 6.78 | Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial. ( Kurita, M; Nishino, S; Numata, Y; Okubo, Y; Sato, T; Takeyoshi, K; Tateno, A; Teranishi, M, 2013) |
| "The treatment with risperidone was well tolerated." | 6.72 | [Changeover to risperidone after treatment with conventional low potency neuroleptics in dementia patients. An observation study during usage]. ( Schmitt, AB; Schreiner, A; Stoppe, G, 2006) |
| "Dementia is associated with progressive cognitive impairment and behavioral and psychological symptoms." | 6.71 | Evaluation of risperidone in the treatment of behavioral and psychological symptoms and sleep disturbances associated with dementia. ( Diago, JI; Durán, JC; Gallego, R; Greenspan, A; Martinez, G, 2005) |
| "Despite the scarcity of high-quality evidence, risperidone is probably the best pharmacological option to consider for alleviating NPS in people with dementia in short-term treatment when considering the risk-benefit profile of drugs." | 5.41 | Pharmacological treatment of neuropsychiatric symptoms of dementia: a network meta-analysis. ( Cai, WJ; Chen, KL; Chen, SD; Dong, Q; Feng, L; Giovane, CD; Huang, SY; Huang, YY; Kuo, K; Li, CB; Liu, CY; Shen, XN; Suckling, J; Teng, T; Wang, RZ; Yu, JT; Zhang, C; Zhao, QH; Zhou, XY, 2023) |
| "Domperidone is a dopamine D₂ receptor antagonist that does not usually cross the blood-brain barrier." | 5.37 | Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia. ( Bocti, C; Hottin, P; Landry, J; Roy-Desruisseaux, J; Tessier, D; Trudel, JF, 2011) |
| "Risperidone was well tolerated overall and nursing staff viewed it as helpful in 38 of 100 patients, moderately helpful in 26, slightly helpful in 17, and not helpful in 19." | 5.30 | Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. ( Goldberg, J; Goldberg, RJ, 1997) |
| "Overall results demonstrate that, compared with placebo, quetiapine is not associated with improvement in psychosis in patients with dementia, while olanzapine and aripiprazole have non-significant small numerical improvements." | 5.22 | Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis. ( Abler, VC; Demos, GN; Mahadik, BS; Rajagopalan, K; Rashid, N; Yunusa, I, 2022) |
| "To examine the effects of galantamine and risperidone on neuropsychiatric symptoms in dementia (NPSD) and global function." | 5.19 | Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial. ( Eriksdotter, M; Freund-Levi, Y; Jedenius, E; Lärksäter, M; Tysen-Bäckström, AC; Wahlund, LO, 2014) |
| "To examine the effects of galantamine and risperidone on agitation in patients with dementia." | 5.19 | Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study. ( Aarsland, D; Auestad, B; Bloniecki, V; Freund-Levi, Y; Lärksäter, M; Tysen Bäckström, AC, 2014) |
| "When comparing treatment effects on individual symptoms frequently occurring in patients with dementia, risperidone significantly improved symptoms of agitation, wandering, diurnal rhythm disturbance and anxieties, among other symptoms, compared with haloperidol." | 5.12 | Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia. ( Choi, SK; Greenspan, AJ; Suh, GH, 2006) |
| "In this study we directly compared the efficacy and tolerability of the atypical antipsychotics quetiapine and risperidone in elderly patients with dementia and symptoms of disturbed perception, thought content, mood or behaviour (behavioural and psychological symptoms of dementia-BPSD)." | 5.12 | Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function. ( Haushofer, M; Pfolz, H; Rainer, M; Struhal, C; Wick, W, 2007) |
| "To compare citalopram and risperidone for the treatment of psychotic symptoms and agitation associated with dementia, with a priori hypotheses that risperidone would be more efficacious for psychosis and citalopram for agitation." | 5.12 | A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. ( Blakesley, RE; Houck, PR; Huber, KA; Mazumdar, S; Mulsant, BH; Pollock, BG; Rosen, J, 2007) |
| "Large randomized controlled trials have shown that risperidone reduces the frequency and severity of behavioral and psychological symptoms of dementia (BPSD) in patients with dementia." | 5.11 | Efficacy of risperidone for treating patients with behavioral and psychological symptoms of dementia. ( Wancata, J, 2004) |
| "To compare risperidone treatment with placebo for the burden to nursing staff of older nursing-home residents with dementia." | 5.11 | The effect of risperidone on nursing burden associated with caring for patients with dementia. ( Brodaty, H; Ciesla, G; Frank, L; Kleinman, L; Rupnow, MF, 2004) |
| "To examine the effect of risperidone on specific behavioral and psychological symptoms of dementia (BPSD)." | 5.11 | Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. ( Brodaty, H; Davidson, M; De Deyn, PP; Greenspan, A; Katz, IR; Rabinowitz, J, 2004) |
| "Eighty-six patients with probable Alzheimer's disease, vascular dementia, or mixed-etiology dementia (DSM-IV criteria) were randomly assigned to treatment with olanzapine or risperidone." | 5.11 | Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. ( Bastean, JN; Bossie, CA; Gharabawi, GM; Greenspan, AJ; Mao, L; Martinez, RA; Mulsant, BH; Pollock, BG; Tune, LE, 2004) |
| " Dementia patients with behavioral and psychological symptoms received risperidone for 3 months." | 5.11 | Open-label, observational study of the effects of risperidone on the behavioral and psychological symptoms of dementia and caregiver stress in the community setting. ( Antonio Burón, J; Arriola, E; Gallego, R; Ignacio Diago, J, 2005) |
| "Risperidone significantly improves behavioral and psychological symptoms of dementia (BPSD), including aggression, agitation and psychosis, as shown by randomized, placebo-controlled trials." | 5.11 | Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice. ( Kurz, A; Schmitt, A; Schwalen S, S, 2005) |
| "In a double-blind parallel study allowing dose titration over 14 days, 39 agitated persons with DSM-IV dementia who were residing in long-term care facilities were administered olanzapine (N = 20) or risperidone (N = 19) as acute treatment." | 5.10 | A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. ( Fontaine, CS; Hynan, LS; Koch, K; Martin-Cook, K; Svetlik, D; Weiner, MF, 2003) |
| "To compare the effects of risperidone and olanzapine on cognition in elderly patients with dementia and psychosis, and to compare the side effects of these drugs." | 5.10 | Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis. ( Arndt, S; Ekstam-Smith, K; Ellingrod, VL; Kutscher, E; Schultz, SK; Turvey, C, 2002) |
| "65 patients suffering from AD, 10 from vascular dementia, and 15 from both were randomized to open label rivastigmine and risperidone, alone or in combination, for 20 weeks." | 5.10 | A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. ( Anand, R; Cicin-Sain, A; Hartman, R; Korczyn, AD; Rotmensch, HH; Weiser, M, 2002) |
| "We report the findings from the first large, double-blind, placebo-controlled study conducted to evaluate the efficacy and safety of risperidone in the treatment of psychotic and behavioral symptoms in institutionalized elderly patients with dementia." | 5.09 | Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. ( Brecher, M; Clyde, C; Jeste, DV; Katz, IR; Mintzer, JE; Napolitano, J, 1999) |
| "The authors studied the incidence of tardive dyskinesia in elderly institutionalized patients with dementia being treated with risperidone." | 5.09 | Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. ( Jeste, DV; Kane, JM; Martinez, RA; Napolitano, J; Okamoto, A, 2000) |
| "Risperidone was used to treat 11 elderly hospitalized patients between 61 and 79 years of age who manifested signs of psychoses related to schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia." | 5.08 | Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. ( Abaza, A; Araujo, L; Brenner, R; Madhusoodanan, S, 1995) |
| "This pilot study investigated effectiveness and tolerability of risperidone for the treatment of psychosis and agitation in 9 inpatients with Parkinson's disease and dementia." | 5.08 | The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. ( Bakey, AA; Kunik, ME; Molinari, VA; Orengo, CA; Workman, RH, 1997) |
| "The efficacy and safety of risperidone, haloperidol, and thioridazine for treating dementia-associated behavioral disturbances were evaluated in a retrospective study of 186 patients aged 65 years or older with DSM-III-R or DSM-IV diagnoses of Alzheimer's dementia, senile dementia NOS, or organic brain syndrome." | 5.08 | Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances. ( Frenchman, IB; Prince, T, 1997) |
| "The authors describe a series of 22 patients with dementia and behavioral disturbances, including agitation, aggression, delusions, and hallucinations, who were treated with risperidone." | 5.08 | Risperidone for the treatment of behavioral disturbances in dementia: a case series. ( Campbell, B; Flynn, M; Herrmann, N; Rabheru, K; Rivard, MF; Ward, C, 1998) |
| "Risperidone, serotonin reuptake inhibitors as a class and dextromethorphan/quinidine demonstrated evidence of efficacy for agitation in dementia, although findings for dextromethorphan/quinidine were based on a single RCT." | 4.98 | Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis. ( Bell, JS; Chaiyakunapruk, N; Hilmer, SN; Kongpakwattana, K; Sawangjit, R; Tawankanjanachot, I, 2018) |
| "Data from all double-blind randomised controlled trials of risperidone in dementia patients (risperidone n = 1009, placebo n = 712) were included." | 4.93 | Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients. ( Berlin, JA; Coppola, D; Costafreda, SG; Hough, D; Howard, R; Karcher, K, 2016) |
| "Randomized, controlled trials of antidepressants (selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, trazodone, and other antidepressants), compared to either placebo or comparator medications (typical or atypical antipsychotics, anticonvulsants, benzodiazepines, cholinesterase inhibitors, memantine or other medications) for treatment of agitation or psychosis in older adults with dementia." | 4.87 | Antidepressants for agitation and psychosis in dementia. ( Adunuri, N; Gill, SS; Gruneir, A; Herrmann, N; Rochon, P; Seitz, DP, 2011) |
| "This study is a meta-analysis of patients with psychosis of AD from four large placebo-controlled clinical trials of risperidone in dementia." | 4.84 | The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. ( Brodaty, H; de Deyn, PP; Greenspan, A; Katz, I; Mintzer, J; Zhu, Y, 2007) |
| "Post hoc analyses of pooled results from 11 randomised controlled trials of risperidone and olanzapine in elderly dementia subjects revealed an increased incidence of cerebrovascular adverse events compared with placebo." | 4.82 | Do atypical antipsychotics cause stroke? ( Herrmann, N; Lanctôt, KL, 2005) |
| "Post-hoc analysis by the pharmaceutical company Eli Lilly of 5 randomised clinical trials concerning the efficacy ofolanzapine in patients with dementia, has shown that patients taking olanzapine have a risk of experiencing a cerebrovascular accident which is 3 times higher than patients taking placebo." | 4.82 | [Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia]. ( Jansen, PA; van Marum, RJ, 2005) |
| "To compare the efficacy and safety of risperidone and olanzapine in the treatment of psychotic symptoms and behavioural disturbances in institutionalised patients with dementia and other psychiatric disorders." | 4.82 | Atypical antipsychotics for nursing home patients: a retrospective chart review. ( Frenchman, IB, 2005) |
| "There is a now a substantial body of evidence that suggests the new antipsychotic agent, risperidone, may be safe and effective for treating psychotic, affective or behavioural symptoms associated with various disorders other than schizophrenia, schizophreniform disorder or schizo-affective disorder." | 4.81 | Does risperidone have a place in the treatment of nonschizophrenic patients? ( Schweitzer, I, 2001) |
| "Relevant data relating to the dosage of risperidone identified through an online (MEDLINE) search using the keywords risperidone, schizophrenia, schizoaffective disorder dementia, bipolar disorder, and dose were supplemented by a review of international and U." | 4.81 | Optimal dosing with risperidone: updated recommendations. ( Williams, R, 2001) |
| "Advances in the assessment of the behavioral and psychological symptoms of dementia (BPSD) have been employed in large-scale clinical trials of new antipsychotic medications such as risperidone." | 4.81 | Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. ( De Deyn, PP; Wirshing, WC, 2001) |
| "Risperidone offers physicians the unique combination of extensive, published clinical experience and a good safety profile for treating patients with dementia who have symptoms of aggression, agitation, and psychosis." | 4.81 | Risperidone for the treatment of behavioral and psychological symptoms of dementia. ( Tune, LE, 2001) |
| "Currently available research on the use of risperidone to manage agitation in patients with dementia is discussed." | 4.80 | Risperidone for control of agitation in dementia patients. ( Falsetti, AE, 2000) |
| "The efficacy of risperidone has been demonstrated in the treatment of the behavioural and psychological symptoms associated with dementia in the elderly." | 4.80 | Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia. ( Bhana, N; Spencer, CM, 2000) |
| "We used Pharmaceutical Benefits Scheme dispensing claims to identify patients who initiated donepezil, rivastigmine, galantamine or memantine between 1 January 2013 and 30 June 2017 (after a period of ≥180 days with no dispensing of these medicines) and remained on therapy for ≥180 days (n = 4393), and dispensed anticholinergic medicines in the 180 days before and after initiating dementia medicines." | 3.91 | Anticholinergic medicines use among older adults before and after initiating dementia medicines. ( Buckley, N; Le Couteur, DG; Litchfield, M; McLachlan, AJ; Narayan, SW; Pearson, SA; Zoega, H, 2019) |
| "The aim of this study was to compare the efficacy and side-effect profile of the typical antipsychotic haloperidol with that of the atypical antipsychotics risperidone, olanzapine, and aripiprazole in the management of delirium." | 3.81 | Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects. ( Boettger, S; Breitbart, W; Jenewein, J, 2015) |
| "Second-generation antipsychotic (SGA) monotherapy was the most common type of therapy in both those with dementia and with schizophrenia, and quetiapine and risperidone were the most commonly prescribed drugs for these conditions, respectively." | 3.81 | Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital. ( Chang, YS; Lai, CY; Wu, YH, 2015) |
| " Department of Veterans Affairs (fiscal years 1999-2008) for dementia patients age 65 and older who began outpatient treatment with an antipsychotic (risperidone, olanzapine, quetiapine, or haloperidol) or valproic acid and its derivatives (as a nonantipsychotic comparison)." | 3.78 | Risk of mortality among individual antipsychotics in patients with dementia. ( Blow, FC; Chiang, C; Cunningham, F; Kales, HC; Kim, HM; Schneider, LS; Seyfried, LS; Valenstein, M; Zivin, K, 2012) |
| "We compared the incidence of parkinsonism after new treatment with risperidone, olanzapine, or quetiapine in patients with dementia and examined the effects of dose and sex on the risk of parkinsonism." | 3.78 | Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex. ( Anderson, GM; Fischer, HD; Herrmann, N; Marras, C; Rochon, PA; Wang, X, 2012) |
| "Patients with a diagnosis of dementia and in treatment with AA (risperidone, olanzapine, and quetiapine) were selected from three main Alzheimer Evaluation Centers (Geriatrics, Neurology, Internal Medicine) of the University Hospital in Ferrara, in the period 05/2003-04/2006." | 3.76 | Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara. ( Bianchi, S; Chiabrando, G; Montanaro, N; Poluzzi, E; Scanavacca, P, 2010) |
| "This study was intended to compare the consistency of risperidone exposure in patients who have dementia and behavioral disturbances treated in a psychiatric hospital versus a community care setting." | 3.73 | Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances. ( Bies, RR; Huber, KA; Kirshner, MA; Mulsant, BH; Pollock, BG; Rosen, J; Wilson, NL, 2005) |
| "Following changes in the safety information on the use of risperidone and olanzapine in elderly patients with dementia, data from prescription-event monitoring (PEM) studies of risperidone, quetiapine and olanzapine were examined." | 3.73 | Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. ( Harris, S; Layton, D; Shakir, SA; Wilton, LV, 2005) |
| "In March 2004, the UK Committee of Safety of Medicines (CSM) informed clinicians that risperidone and olanzapine should not be used to treat behavioural and psychological symptoms of dementia (BPSD) because of increased risk of strokes with both drugs and increased risk of mortality with olanzapine." | 3.73 | Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued? ( Shah, A, 2006) |
| "Olanzapine and risperidone use were not associated with a statistically significant increased risk of stroke compared with typical antipsychotic use." | 3.72 | Atypical antipsychotics and risk of cerebrovascular accidents. ( Herrmann, N; Lanctôt, KL; Mamdani, M, 2004) |
| " Three nursing-home residents who suffered from multiple somatic disorders and dementia, two men aged 78 and 76 years respectively and a woman aged 72 years, developed neuroleptic malignant syndrome following the use of risperidone." | 3.72 | [Neuroleptic malignant syndrome in users of risperidone]. ( de Jonghe-Rouleau, AP; Gerritsen, AA; Stienstra-Liem, LH, 2004) |
| "Risperidone was also found to be more efficacious than placebo (SMD -0." | 2.82 | Pharmacological treatments for psychotic symptoms in dementia: A systematic review with pairwise and network meta-analysis. ( Chen, KL; Chen, SD; Dong, Q; Dou, KX; Huang, YY; Shen, XN; Tan, L; Teng, T; Wang, J; Wang, RZ; Yu, JT; Zhang, RQ; Zhao, QH; Zhong, XL; Zhou, XY, 2022) |
| " We conducted an 8-week, rater-blinded, randomized trial, administering flexibly dosed risperidone, yokukansan, or fluvoxamine." | 2.78 | Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial. ( Kurita, M; Nishino, S; Numata, Y; Okubo, Y; Sato, T; Takeyoshi, K; Tateno, A; Teranishi, M, 2013) |
| "In this systematic literature review (SLR), we qualitatively synthesized evidence on the comparative efficacy (based on neuropsychiatric inventory), tolerability (weight gain), and safety (cerebrovascular adverse events [CVAE], cardiovascular events, mortality, somnolence, extrapyramidal symptoms [EPS]) of AAPs used to treat DRP." | 2.72 | Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review. ( Abler, V; Rajagopalan, K; Rashid, N; Yunusa, I, 2021) |
| " Dosing strategies, discontinuation considerations, and side effects are discussed." | 2.72 | The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia. ( Chen, A; Cloutier, A; Copeli, F; Metzger, E; Osser, DN, 2021) |
| "The treatment with risperidone was well tolerated." | 2.72 | [Changeover to risperidone after treatment with conventional low potency neuroleptics in dementia patients. An observation study during usage]. ( Schmitt, AB; Schreiner, A; Stoppe, G, 2006) |
| "Dementia is associated with progressive cognitive impairment and behavioral and psychological symptoms." | 2.71 | Evaluation of risperidone in the treatment of behavioral and psychological symptoms and sleep disturbances associated with dementia. ( Diago, JI; Durán, JC; Gallego, R; Greenspan, A; Martinez, G, 2005) |
| "Aripiprazole has the most consistent evidence of symptom improvement; however, this improvement is small." | 2.53 | Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use. ( Cocker, KE; Reese, TR; Thiel, DJ, 2016) |
| " It is well-tolerated and rather safe for elderly patients." | 2.48 | [Efficasy and safety of the use of risperidone (rispoluxe) in demented patients with psychotic and behavioural disorders]. ( Bocharov, AV; Kondakova, VE; Tuleninov, ES, 2012) |
| "Hallucinations and psychosis are common in patients with Parkinson's disease (PD), with reported prevalences of up to 48% and 80%, respectively." | 2.46 | Management of hallucinations and psychosis in Parkinson's disease. ( Eng, ML; Welty, TE, 2010) |
| "In 2 pivotal trials comparing risperidone with placebo, the risk of adverse events was similar in both treatment groups when risperidone was given at the optimal clinical dose (1 mg/day)." | 2.41 | Long-term safety of risperidone. ( Davidson, M, 2001) |
| " Dosing requirements for elderly patients tend to be much lower than those for younger adults." | 2.40 | Conventional vs. newer antipsychotics in elderly patients. ( Harris, MJ; Jeste, DV; Lacro, J; Lohr, JB; Rockwell, E, 1999) |
| "Significant consequences of untreated psychosis in patients with dementia have led clinicians to seek improved therapeutic options." | 2.40 | Pharmacologic management of psychosis in dementia. ( Schneider, LS, 1999) |
| "Degenerative dementia is characterized by progressive cognitive decline and neuropsychiatric symptoms." | 1.72 | Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography. ( Aarsland, D; Andersson, T; Berglund, A; Cummings, J; Freund-Levi, Y; Holmgren, S, 2022) |
| " Atypical antipsychotic dosages were standardized using a defined daily dose, and the cumulative dosage was calculated." | 1.62 | Atypical Antipsychotics Augmentation in Patients with Depressive Disorder and Risk of Subsequent Dementia: A Nationwide Population-Based Cohort Study. ( Ha, TH; Kim, DK; Kim, H; Kim, J; Kim, K; Lee, EM; Lee, H; Lewis, M; Myung, W; Won, HH, 2021) |
| "There were 291 residents treated with anti-dementia medicines, 129 (44%) of whom received antipsychotics concomitantly with an anti-dementia medicine." | 1.43 | The use of antipsychotics among people treated with medications for dementia in residential aged care facilities. ( Gadzhanova, S; Pont, LG; Roughead, EE; Shin, HY; Ward, MB, 2016) |
| "Risperidone was analysed separately, in accordance with its limited licence for use in older adults with dementia, granted in October 2008." | 1.42 | Second-generation antipsychotic drug use in hospital inpatients with dementia: the impact of a safety warning on rates of prescribing. ( Coleman, JJ; McIlroy, G; Thomas, SK, 2015) |
| " Although our study suggests the prescription dosage and duration of antipsychotic treatment decreased significantly after FDA warning in 2005, the duration of treatment was still long." | 1.42 | Dosage and duration of antipsychotic treatment in demented outpatients with agitation or psychosis. ( Chiang, HL; Hwang, TJ; Hwu, HG; Lin, YT; Shan, JC; Sheu, YH, 2015) |
| " As a group, the atypical antipsychotics (olanzapine, quetiapine, and risperidone) showed a dose-response increase in mortality risk, with 3." | 1.42 | Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. ( Chiang, C; Kales, HC; Kavanagh, J; Kim, HM; Maust, DT; Schneider, LS; Seyfried, LS, 2015) |
| "Haloperidol was associated with higher mortality risk (HR 30 days = 1." | 1.40 | Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. ( Aarsland, D; Ballard, C; Engdahl, B; Langballe, EM; Nordeng, H; Selbæk, G, 2014) |
| " There was a dose-response relation for all drugs except quetiapine." | 1.38 | Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. ( Avorn, J; Crystal, S; Gerhard, T; Huybrechts, KF; Levin, R; Lucas, JA; Olfson, M; Schneeweiss, S, 2012) |
| "Domperidone is a dopamine D₂ receptor antagonist that does not usually cross the blood-brain barrier." | 1.37 | Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia. ( Bocti, C; Hottin, P; Landry, J; Roy-Desruisseaux, J; Tessier, D; Trudel, JF, 2011) |
| " Further investigations are warranted to identify patient characteristics and antipsychotic dosage regimens that are not associated with a greater risk of mortality in elderly patients with dementia." | 1.36 | Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia? ( Dysken, MW; Lederle, FA; Rector, TS; Rossom, RC, 2010) |
| "Risperidone and promazine were the most frequently prescribed antipsychotic; 40." | 1.35 | Use and misuse of antipsychotic drugs in patients with dementia in Alzheimer special care units. ( Lucca, U; Matucci, M; Nobili, A; Pasina, L; Riva, E; Tarantola, M; Tettamanti, M; Trevisan, S, 2009) |
| " Most people did not have any adverse effects; 5 patients (15." | 1.34 | Behavioral and psychological symptoms of dementia (BPSD) in elderly demented subjects: is the long lasting use of atypical antipsychotic drugs useful and safe? ( Angelini, A; Bendini, C; Neri, M; Neviani, F, 2007) |
| "Risperidone was the most frequently prescribed antipsychotic (n = 136, 44." | 1.33 | Psychotropic drug use in older people with mental illness with particular reference to antipsychotics: a systematic study of tolerability and use in different diagnostic groups. ( Curran, S; Musa, S; Turner, D; Wattis, J, 2005) |
| "With risperidone treatment, the vocalizations diminished to less than 20% of baseline ratings." | 1.30 | The use of risperidone in severely demented patients with persistent vocalizations. ( Honer, WG; Kopala, LC, 1997) |
| "Risperidone was well tolerated overall and nursing staff viewed it as helpful in 38 of 100 patients, moderately helpful in 26, slightly helpful in 17, and not helpful in 19." | 1.30 | Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. ( Goldberg, J; Goldberg, RJ, 1997) |
| "Risperidone was an effective and safe treatment in three cases of delusions of infestation." | 1.30 | Risperidone in the treatment of delusions of infestation. ( Bailey, LG; Canterbury, AL; De León, OA; Furmaga, KM, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (13.66) | 18.2507 |
| 2000's | 106 (57.92) | 29.6817 |
| 2010's | 43 (23.50) | 24.3611 |
| 2020's | 9 (4.92) | 2.80 |
| Authors | Studies |
|---|---|
| Kołaczkowski, M | 1 |
| Marcinkowska, M | 1 |
| Bucki, A | 1 |
| Pawłowski, M | 1 |
| Mitka, K | 1 |
| Jaśkowska, J | 1 |
| Kowalski, P | 1 |
| Kazek, G | 1 |
| Siwek, A | 1 |
| Wasik, A | 1 |
| Wesołowska, A | 1 |
| Mierzejewski, P | 1 |
| Bienkowski, P | 1 |
| Yunusa, I | 2 |
| Rashid, N | 2 |
| Abler, V | 1 |
| Rajagopalan, K | 2 |
| Huang, YY | 2 |
| Teng, T | 2 |
| Shen, XN | 2 |
| Chen, SD | 2 |
| Wang, RZ | 2 |
| Zhang, RQ | 1 |
| Dou, KX | 1 |
| Zhong, XL | 1 |
| Wang, J | 1 |
| Chen, KL | 2 |
| Zhao, QH | 2 |
| Tan, L | 1 |
| Dong, Q | 2 |
| Zhou, XY | 2 |
| Yu, JT | 2 |
| Demos, GN | 1 |
| Mahadik, BS | 1 |
| Abler, VC | 1 |
| Holmgren, S | 1 |
| Andersson, T | 1 |
| Berglund, A | 1 |
| Aarsland, D | 6 |
| Cummings, J | 1 |
| Freund-Levi, Y | 4 |
| Rogowska, M | 2 |
| Thornton, M | 2 |
| Creese, B | 2 |
| Velayudhan, L | 2 |
| Ballard, C | 6 |
| Tsamakis, K | 2 |
| Stewart, R | 2 |
| Mueller, C | 2 |
| Seifert, J | 1 |
| Maier, HB | 1 |
| Toto, S | 1 |
| Dabbert, D | 1 |
| Giovane, CD | 1 |
| Suckling, J | 1 |
| Huang, SY | 1 |
| Kuo, K | 1 |
| Cai, WJ | 1 |
| Feng, L | 1 |
| Zhang, C | 1 |
| Liu, CY | 1 |
| Li, CB | 1 |
| Chen, A | 1 |
| Copeli, F | 1 |
| Metzger, E | 1 |
| Cloutier, A | 1 |
| Osser, DN | 1 |
| Kim, J | 1 |
| Ha, TH | 1 |
| Kim, K | 1 |
| Lee, EM | 1 |
| Kim, H | 1 |
| Kim, DK | 1 |
| Won, HH | 1 |
| Lewis, M | 1 |
| Lee, H | 1 |
| Myung, W | 1 |
| Nerius, M | 1 |
| Johnell, K | 1 |
| Garcia-Ptacek, S | 1 |
| Eriksdotter, M | 3 |
| Haenisch, B | 1 |
| Doblhammer, G | 1 |
| Kongpakwattana, K | 1 |
| Sawangjit, R | 1 |
| Tawankanjanachot, I | 1 |
| Bell, JS | 1 |
| Hilmer, SN | 1 |
| Chaiyakunapruk, N | 1 |
| Xue, XJ | 1 |
| He, RL | 1 |
| Li, WX | 1 |
| Xin, JW | 1 |
| Ye, QY | 1 |
| Chen, XC | 1 |
| Pan, XD | 1 |
| Narayan, SW | 1 |
| Pearson, SA | 1 |
| Litchfield, M | 1 |
| Le Couteur, DG | 1 |
| Buckley, N | 1 |
| McLachlan, AJ | 1 |
| Zoega, H | 1 |
| Vasilyeva, I | 1 |
| Biscontri, RG | 1 |
| Enns, MW | 1 |
| Metge, CJ | 1 |
| Alessi-Severini, S | 1 |
| Gurwitz, D | 1 |
| Morag, A | 1 |
| Oved, K | 1 |
| Teranishi, M | 1 |
| Kurita, M | 1 |
| Nishino, S | 1 |
| Takeyoshi, K | 1 |
| Numata, Y | 1 |
| Sato, T | 1 |
| Tateno, A | 1 |
| Okubo, Y | 1 |
| Langballe, EM | 1 |
| Engdahl, B | 1 |
| Nordeng, H | 1 |
| Selbæk, G | 1 |
| Jedenius, E | 2 |
| Tysen-Bäckström, AC | 2 |
| Lärksäter, M | 3 |
| Wahlund, LO | 2 |
| McIlroy, G | 1 |
| Thomas, SK | 1 |
| Coleman, JJ | 1 |
| Bloniecki, V | 1 |
| Auestad, B | 1 |
| Tysen Bäckström, AC | 1 |
| Bogaisky, M | 1 |
| Boettger, S | 1 |
| Jenewein, J | 1 |
| Breitbart, W | 1 |
| Corbett, A | 1 |
| Burns, A | 2 |
| Phizackerley, D | 1 |
| Wu, YH | 1 |
| Lai, CY | 1 |
| Chang, YS | 1 |
| Marston, L | 1 |
| Nazareth, I | 1 |
| Petersen, I | 1 |
| Walters, K | 1 |
| Osborn, DP | 1 |
| Reifler, BV | 1 |
| Blazer, D | 1 |
| Lin, YT | 1 |
| Hwang, TJ | 1 |
| Shan, JC | 1 |
| Chiang, HL | 1 |
| Sheu, YH | 1 |
| Hwu, HG | 1 |
| Kim, HM | 3 |
| Chiang, C | 3 |
| Weintraub, D | 1 |
| Schneider, LS | 4 |
| Kales, H | 1 |
| Maust, DT | 1 |
| Seyfried, LS | 2 |
| Kavanagh, J | 1 |
| Kales, HC | 2 |
| Shin, HY | 1 |
| Gadzhanova, S | 1 |
| Roughead, EE | 1 |
| Ward, MB | 1 |
| Pont, LG | 1 |
| Howard, R | 2 |
| Costafreda, SG | 1 |
| Karcher, K | 1 |
| Coppola, D | 1 |
| Berlin, JA | 1 |
| Hough, D | 1 |
| Sultana, J | 1 |
| Fontana, A | 1 |
| Giorgianni, F | 1 |
| Pasqua, A | 1 |
| Cricelli, C | 1 |
| Spina, E | 1 |
| Gambassi, G | 1 |
| Ivanovic, J | 1 |
| Ferrajolo, C | 1 |
| Molokhia, M | 1 |
| Sharp, S | 1 |
| Sturkenboom, M | 1 |
| Trifirò, G | 1 |
| Reese, TR | 1 |
| Thiel, DJ | 1 |
| Cocker, KE | 1 |
| Lapeyre-Mestre, M | 1 |
| Forlenza, OV | 1 |
| Cretaz, E | 1 |
| Diniz, BS | 1 |
| Kálmán, J | 1 |
| Kálmán, S | 1 |
| Pákáski, M | 1 |
| Kalapatapu, RK | 1 |
| Schimming, C | 1 |
| Landreville, P | 1 |
| Leblanc, V | 1 |
| Chan, MC | 1 |
| Chong, CS | 1 |
| Wu, AY | 1 |
| Wong, KC | 1 |
| Dunn, EL | 1 |
| Tang, OW | 1 |
| Chan, WF | 1 |
| Sanfélix-Gimeno, G | 1 |
| Cervera-Casino, P | 1 |
| Peiró, S | 1 |
| López-Valcarcel, BG | 1 |
| Blázquez, A | 1 |
| Barbera, T | 1 |
| Dombrovski, AY | 1 |
| Mulsant, BH | 5 |
| Ferrell, RE | 1 |
| Lotrich, FE | 1 |
| Rosen, JI | 1 |
| Wallace, M | 1 |
| Houck, PR | 3 |
| Mazumdar, S | 3 |
| Pollock, BG | 5 |
| Duggal, H | 1 |
| Singh, I | 1 |
| Chiabrando, G | 1 |
| Bianchi, S | 1 |
| Poluzzi, E | 1 |
| Montanaro, N | 1 |
| Scanavacca, P | 1 |
| Rossom, RC | 1 |
| Rector, TS | 1 |
| Lederle, FA | 1 |
| Dysken, MW | 1 |
| Eng, ML | 1 |
| Welty, TE | 1 |
| Seitz, DP | 1 |
| Adunuri, N | 1 |
| Gill, SS | 1 |
| Gruneir, A | 1 |
| Herrmann, N | 5 |
| Rochon, P | 1 |
| Nobili, A | 1 |
| Pasina, L | 1 |
| Trevisan, S | 1 |
| Riva, E | 1 |
| Lucca, U | 1 |
| Tettamanti, M | 1 |
| Matucci, M | 1 |
| Tarantola, M | 1 |
| Roy-Desruisseaux, J | 1 |
| Landry, J | 1 |
| Bocti, C | 1 |
| Tessier, D | 1 |
| Hottin, P | 1 |
| Trudel, JF | 1 |
| Zivin, K | 1 |
| Valenstein, M | 1 |
| Cunningham, F | 1 |
| Blow, FC | 1 |
| Huybrechts, KF | 1 |
| Gerhard, T | 1 |
| Crystal, S | 1 |
| Olfson, M | 1 |
| Avorn, J | 2 |
| Levin, R | 1 |
| Lucas, JA | 1 |
| Schneeweiss, S | 2 |
| Meguro, K | 1 |
| Meguro, M | 1 |
| Akanuma, K | 1 |
| Bocharov, AV | 1 |
| Kondakova, VE | 1 |
| Tuleninov, ES | 1 |
| Marras, C | 1 |
| Anderson, GM | 1 |
| Fischer, HD | 1 |
| Wang, X | 1 |
| Rochon, PA | 1 |
| Ismail, Z | 1 |
| Emeremni, CA | 1 |
| Rosen, J | 3 |
| Rajji, TK | 1 |
| Bullock, R | 1 |
| Saharan, A | 1 |
| Wooltorton, E | 1 |
| McIntyre, RS | 1 |
| Motsinger, CD | 1 |
| Perron, GA | 1 |
| Lacy, TJ | 1 |
| Fontaine, CS | 1 |
| Hynan, LS | 1 |
| Koch, K | 1 |
| Martin-Cook, K | 1 |
| Svetlik, D | 1 |
| Weiner, MF | 1 |
| Kurz, A | 2 |
| Delius-Stute, H | 1 |
| Rettig, K | 1 |
| Schwalen, S | 1 |
| Mahmoud, R | 2 |
| Greenspan, A | 5 |
| Saxe, T | 1 |
| Watanabe, H | 1 |
| Tominaga, K | 1 |
| Ogino, A | 1 |
| Sekino, K | 1 |
| Aoba, A | 1 |
| Grossman, F | 1 |
| Okamoto, A | 2 |
| Turkoz, I | 1 |
| Gharabawi, G | 1 |
| Mowat, D | 1 |
| Fowlie, D | 1 |
| MacEwan, T | 1 |
| Mamdani, M | 1 |
| Lanctôt, KL | 2 |
| Wancata, J | 2 |
| Tariot, PN | 3 |
| Profenno, LA | 1 |
| Ismail, MS | 1 |
| Ballard, CG | 2 |
| Margallo-Lana, ML | 1 |
| Frank, L | 1 |
| Kleinman, L | 1 |
| Ciesla, G | 1 |
| Rupnow, MF | 1 |
| Brodaty, H | 5 |
| Rabinowitz, J | 2 |
| Katz, IR | 4 |
| De Deyn, PP | 7 |
| Davidson, M | 3 |
| Gerritsen, AA | 1 |
| de Jonghe-Rouleau, AP | 1 |
| Stienstra-Liem, LH | 1 |
| Tran, KT | 1 |
| Golden, P | 1 |
| Goldman, P | 1 |
| Lark, T | 1 |
| Jacob, NJ | 1 |
| Englert, I | 1 |
| Gharabawi, GM | 1 |
| Bossie, CA | 1 |
| Mao, L | 1 |
| Martinez, RA | 2 |
| Tune, LE | 2 |
| Greenspan, AJ | 3 |
| Bastean, JN | 1 |
| Warner, J | 1 |
| Butler, R | 1 |
| Arya, P | 1 |
| van Waarde, JA | 1 |
| Kuiper, J | 1 |
| Verwey, B | 1 |
| Kroon, JG | 1 |
| Bonte-Mineur, F | 1 |
| Geerlings, CJ | 1 |
| Rietveld, AP | 1 |
| Vorel, SK | 1 |
| Bos, F | 1 |
| Vorel-Havelkova, E | 1 |
| Brombacher, PJ | 1 |
| van Marum, RJ | 1 |
| Jansen, PA | 1 |
| Cruz Jentoft, AJ | 1 |
| Gil Gregorio, P | 1 |
| Altimir Losada, S | 1 |
| van Bemmel, T | 1 |
| Westendorp, RG | 1 |
| Frenchman, IB | 2 |
| Hafkamp, GJ | 1 |
| van der Mast, RC | 1 |
| Zhao, CS | 1 |
| Puurunen, K | 1 |
| Sivenius, J | 1 |
| Jolkkonen, J | 1 |
| Schallert, T | 1 |
| Kuehn, BM | 1 |
| Cream, J | 1 |
| Shah, A | 2 |
| Suh, GH | 3 |
| Formiga, F | 1 |
| Fort, I | 1 |
| Pérez-Castejón, JM | 1 |
| Ruiz, D | 1 |
| Duaso, E | 1 |
| Riu, S | 1 |
| Arriola, E | 1 |
| Ignacio Diago, J | 1 |
| Antonio Burón, J | 1 |
| Gallego, R | 2 |
| Asghar Ali, AA | 1 |
| Espinoza, R | 1 |
| Kavirajan, H | 1 |
| Read, S | 1 |
| Raju, J | 1 |
| Sikdar, S | 1 |
| Krishna, T | 1 |
| Curran, S | 1 |
| Turner, D | 1 |
| Musa, S | 1 |
| Wattis, J | 1 |
| Bies, RR | 1 |
| Huber, KA | 2 |
| Wilson, NL | 1 |
| Kirshner, MA | 1 |
| Layton, D | 1 |
| Harris, S | 1 |
| Wilton, LV | 1 |
| Shakir, SA | 1 |
| Schwalen S, S | 1 |
| Schmitt, A | 1 |
| Durán, JC | 1 |
| Diago, JI | 1 |
| Martinez, G | 1 |
| Finkel, S | 1 |
| Kozma, C | 1 |
| Long, S | 1 |
| Baser, O | 1 |
| Engelhart, L | 1 |
| Katz, I | 2 |
| Cohen-Mansfield, J | 1 |
| Stoppe, G | 1 |
| Schreiner, A | 1 |
| Schmitt, AB | 1 |
| Friedman, JH | 1 |
| Al Chekakie, MO | 1 |
| Ketz, JM | 1 |
| Whinney, CM | 1 |
| Snowdon, J | 1 |
| Ames, D | 1 |
| Day, S | 1 |
| Choi, SK | 2 |
| Zuidema, SU | 1 |
| van Iersel, MB | 1 |
| Koopmans, RT | 1 |
| Verhey, FR | 1 |
| Olde Rikkert, MG | 1 |
| Lolk, A | 1 |
| Gulmann, NC | 1 |
| Haupt, M | 1 |
| Cruz-Jentoft, A | 1 |
| Jeste, D | 1 |
| Nonino, F | 1 |
| De Girolamo, G | 1 |
| Gamberini, L | 1 |
| Goldoni, CA | 1 |
| Jackson, GA | 1 |
| Angelini, A | 1 |
| Bendini, C | 1 |
| Neviani, F | 1 |
| Neri, M | 1 |
| Kudo, T | 1 |
| Mintzer, J | 1 |
| Zhu, Y | 1 |
| Rainer, M | 1 |
| Haushofer, M | 1 |
| Pfolz, H | 1 |
| Struhal, C | 1 |
| Wick, W | 1 |
| Yury, CA | 1 |
| Fisher, JE | 1 |
| Daiello, LA | 1 |
| Blakesley, RE | 1 |
| Wang, PS | 1 |
| Setoguchi, S | 1 |
| Patrick, A | 1 |
| Mogun, H | 1 |
| Choudhry, NK | 1 |
| Brookhart, MA | 1 |
| Czarnecki, K | 1 |
| Kumar, N | 1 |
| Josephs, KA | 1 |
| Jano, E | 1 |
| Johnson, M | 1 |
| Chen, H | 1 |
| Aparasu, RR | 1 |
| Ruths, S | 1 |
| Straand, J | 1 |
| Nygaard, HA | 1 |
| Selbaek, G | 1 |
| Engedal, K | 1 |
| Singh, D | 1 |
| Forlano, R | 1 |
| Athey, R | 1 |
| Williams, S | 1 |
| Bullmore, E | 1 |
| Brammer, M | 1 |
| Mellers, J | 1 |
| Woodruff, P | 1 |
| David, A | 1 |
| Allen, RL | 1 |
| Walker, Z | 1 |
| D'Ath, PJ | 1 |
| Katona, CL | 1 |
| Jeanblanc, W | 1 |
| Davis, YB | 1 |
| McKeith, IG | 1 |
| Harrison, RW | 1 |
| Madhusoodanan, S | 1 |
| Brenner, R | 1 |
| Araujo, L | 1 |
| Abaza, A | 1 |
| Wijeratne, C | 1 |
| Webster, P | 1 |
| Maany, I | 1 |
| Kopala, LC | 1 |
| Honer, WG | 1 |
| Brecher, M | 2 |
| Goldberg, RJ | 1 |
| Goldberg, J | 1 |
| Finkel, SI | 1 |
| Workman, RH | 1 |
| Orengo, CA | 1 |
| Bakey, AA | 1 |
| Molinari, VA | 1 |
| Kunik, ME | 1 |
| Prince, T | 1 |
| De León, OA | 1 |
| Furmaga, KM | 1 |
| Canterbury, AL | 1 |
| Bailey, LG | 1 |
| Geizer, M | 1 |
| Ancill, RJ | 1 |
| Rivard, MF | 1 |
| Flynn, M | 1 |
| Ward, C | 1 |
| Rabheru, K | 2 |
| Campbell, B | 1 |
| Jeste, DV | 3 |
| Rockwell, E | 1 |
| Harris, MJ | 1 |
| Lohr, JB | 1 |
| Lacro, J | 1 |
| Beers, MH | 1 |
| Mintzer, JE | 1 |
| Clyde, C | 1 |
| Napolitano, J | 2 |
| Meares, S | 1 |
| Draper, B | 1 |
| Chengappa, KN | 1 |
| Sheth, S | 1 |
| Brar, JS | 1 |
| Parepally, H | 1 |
| Marcus, S | 1 |
| Gopalani, A | 1 |
| Palmer, A | 1 |
| Baker, RW | 1 |
| Schooler, NR | 1 |
| Rasmussen, A | 1 |
| Bocksberger, JP | 1 |
| Dautzenberg, PL | 1 |
| Eriksson, S | 1 |
| Lawlor, BA | 1 |
| Reynolds, PL | 1 |
| Strayer, SM | 1 |
| Windhaber, J | 1 |
| Urbanits, S | 1 |
| Grisold, W | 1 |
| Reznik, I | 1 |
| Paleacu, D | 1 |
| Masand, PS | 1 |
| Falsetti, AE | 1 |
| Kane, JM | 1 |
| Bhana, N | 1 |
| Spencer, CM | 1 |
| Zaudig, M | 1 |
| Schweitzer, I | 1 |
| Biswas, A | 1 |
| Mittal, P | 1 |
| Chaturvedi, S | 1 |
| Prasad, A | 1 |
| Williams, R | 1 |
| Chaplin, RH | 1 |
| Wirshing, WC | 2 |
| Laks, J | 1 |
| Engelhardt, E | 1 |
| Marinho, V | 1 |
| Rozenthal, M | 1 |
| Souza, FC | 1 |
| Bacaltchuk, J | 1 |
| Stoppe, A | 1 |
| Ferreira, RC | 1 |
| Bottino, C | 1 |
| Scalco, M | 1 |
| Buckley, PF | 1 |
| Ellingrod, VL | 1 |
| Schultz, SK | 1 |
| Ekstam-Smith, K | 1 |
| Kutscher, E | 1 |
| Turvey, C | 1 |
| Arndt, S | 1 |
| Stryjer, R | 1 |
| Bar, F | 1 |
| Strous, RD | 1 |
| Baruch, Y | 1 |
| Rabey, JM | 1 |
| Weiser, M | 1 |
| Rotmensch, HH | 1 |
| Korczyn, AD | 1 |
| Hartman, R | 1 |
| Cicin-Sain, A | 1 |
| Anand, R | 1 |
| Kruglov, LS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feru-guard (Ferulic Acid and Angelica Archangelica Extract) for Behavioral Symptoms in Dementia[NCT03451760] | Phase 2 | 70 participants (Anticipated) | Interventional | 2018-09-30 | Not yet recruiting | ||
| A Pragmatic Randomized-controlled Trial of a Multi-pronged Electronic Health Record-based Clinical Decision Support Tool to Reduce Low-value Antipsychotic Prescriptions Among Older Adults With Alzheimer's and Related Dementias[NCT04851691] | 117 participants (Anticipated) | Interventional | 2021-08-03 | Enrolling by invitation | |||
| Treatment of Psychosis and Agitation in Alzheimer's Disease[NCT02129348] | Phase 2 | 77 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Post Marketing Study of Escitalopram Versus Risperidone for the Treatment of Behavioral and Psychological Symptoms Amongst Alzheimer's Disease Patients[NCT01119638] | Phase 4 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone for Treatment of Behavioral Disturbances in Subjects With Dementia[NCT00253123] | Phase 3 | 626 participants (Actual) | Interventional | Completed | |||
| Risperidone in the Treatment of Behavioral Disturbances in Demented Patients: an International, Multicenter, Placebo-controlled, Double-blind, Parallel-group Trial Using Haloperidol as Internal Reference[NCT00249145] | Phase 3 | 349 participants (Actual) | Interventional | 1995-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Basic Activities of Daily Living with items for 6 functions: bathing, dressing, toileting, transferring, continence, and feeding. Each item is scored as unimpaired=1, impaired=0. Total score is the measure used, range 0-6; higher scores indicate better functioning. (NCT02129348)
Timeframe: Assessed at Week 0, Week2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.3 |
| Placebo Group | 0.1 |
Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain is the measure used that combines symptoms of agitation and aggression. Frequency X Severity rating score, range 0-12. Higher score indicates more agitation and aggressive behavior. (NCT02129348)
Timeframe: Assessed at screening, Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.2 |
| Placebo Group | 2.5 |
Clinical Global Impression (CGI) Behavior Change score is the measure used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Scores ranging from 1-3 indicate improvement. Only patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 8 |
The patient is classified as a responder (score=1) if both criteria are met or as a non-responder (score=0) if both criteria are not met. The first criterion to determine responder status, NPI core score, has a scoring range 0-36; each of the three component scores for symptoms of agitation/aggression, delusions and hallucinations has a scoring range 0-12. For each symptom and the total score, higher score indicates more symptoms. The second criterion to determine responder status, Clinical Global Impression (CGI), is used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Only patients who met both criteria, assessed as change compared to baseline, were counted as responders; all other patients were non-responders. Patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 7 |
30 item questionnaire used to assess degree of cognitive impairment. Orientation, registration, attention/calculation, recall, language, repetitions and commands are assessed. Total score is the measure used; range 0-30, higher scores indicate better global cognitive function. (NCT02129348)
Timeframe: Assessed at Screening, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.9 |
| Placebo Group | 0.9 |
Neuropsychological test used to assess a patient's cognitive ability. The patient is asked to complete small tasks such as drawing shapes and printing their name. They are also asked to remember certain names and objects, such as a cup and a spoon, and the evaluator's first name. Total score is the measure used; range 0-100, higher scores indicate better cognition. (NCT02129348)
Timeframe: Assessed at Week 0, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.1 |
| Placebo Group | -0.0 |
Simpson Angus Scale for Extrapyramidal Sign requires in-person examination to assess gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor, and salivation. Total score is the measure used, range 0-40; higher scores indicate increased severity of signs. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | -0.0 |
| Placebo Group | 0.0 |
Treatment Emergent Symptom Scale that covers 26 somatic symptoms, each rated as present (score=1) or absent (score=0). Total score is the measure used with scoring range 0-26; higher scores indicate more somatic symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.6 |
| Placebo Group | 0.7 |
Young Mania Rating Scale total score is the measure used to assess symptoms that occur in mania; each item is a symptom that is rated for severity. Scoring range 0-60; higher scores indicate more severe symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.1 |
| Placebo Group | 1.1 |
Zarit Caregiver Burden Interview with the caregiver asked to rank 22 items on a scale with responses for each item from 'never' (score 0) to 'nearly always' (score 4). Total score is the measure used; range 0-88 with higher scores indicating greater caregiver burden. (NCT02129348)
Timeframe: Assessed at Week 0, Week 4, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.8 |
| Placebo Group | -0.4 |
48 reviews available for risperidone and Dementia
| Article | Year |
|---|---|
Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review.
Topics: Antipsychotic Agents; Aripiprazole; Dementia; Humans; Olanzapine; Psychotic Disorders; Risperidone | 2021 |
Pharmacological treatments for psychotic symptoms in dementia: A systematic review with pairwise and network meta-analysis.
Topics: Aripiprazole; Dementia; Donepezil; Humans; Memantine; Network Meta-Analysis; Risperidone; United Sta | 2022 |
Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dementia; Humans; Network Meta-Analysis; Off-La | 2022 |
Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Humans; Olanzapine; Psychotic Disorders; Quet | 2023 |
Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Humans; Olanzapine; Psychotic Disorders; Quet | 2023 |
Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Humans; Olanzapine; Psychotic Disorders; Quet | 2023 |
Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Humans; Olanzapine; Psychotic Disorders; Quet | 2023 |
Pharmacological treatment of neuropsychiatric symptoms of dementia: a network meta-analysis.
Topics: Aged; Databases, Factual; Dementia; Galantamine; Humans; Network Meta-Analysis; Randomized Controlle | 2023 |
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia.
Topics: Academic Medical Centers; Aged; Algorithms; Antidepressive Agents; Antipsychotic Agents; Aripiprazol | 2021 |
Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Dementia; Dextromethorphan; Drug Combinations; Humans; Network Meta-Analysis; | 2018 |
[Safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms in dementia: a meta-analysis].
Topics: Antipsychotic Agents; Dementia; Europe; Humans; Risperidone; Schizophrenia | 2018 |
Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients.
Topics: Antipsychotic Agents; Cerebrovascular Disorders; Dementia; Humans; Risperidone | 2016 |
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Basal Ganglia Diseases; Behavior Therapy; | 2016 |
A Review of Adverse Outcomes Associated with Psychoactive Drug Use in Nursing Home Residents with Dementia.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Dementia; Humans; Nursing Homes; | 2016 |
[The use of antipsychotics in patients with dementia].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cerebrovascular Disorders; Dementia; Dementia, | 2008 |
[Recognition and treatment of behavioral and psychological symptoms of dementias: lessons from the CATIE-AD study].
Topics: Affect; Aggression; Antipsychotic Agents; Brain; Caregivers; Conduct Disorder; Dementia; Diagnosis, | 2008 |
Management of hallucinations and psychosis in Parkinson's disease.
Topics: Aged; Antipsychotic Agents; Brief Psychiatric Rating Scale; Clozapine; Comorbidity; Delusions; Demen | 2010 |
Antidepressants for agitation and psychosis in dementia.
Topics: Adult; Antidepressive Agents; Citalopram; Dementia; Humans; Psychomotor Agitation; Psychotic Disorde | 2011 |
[Efficasy and safety of the use of risperidone (rispoluxe) in demented patients with psychotic and behavioural disorders].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cognition; Dementia; Female; Humans; Male; Mental Dis | 2012 |
Atypical antipsychotics: experience and use in the elderly.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Clozapine; | 2002 |
[Dementia induced by antipsychotic drugs].
Topics: Antipsychotic Agents; Butyrophenones; Clozapine; Dementia; Diagnostic and Statistical Manual of Ment | 2004 |
Efficacy of atypical antipsychotics in elderly patients with dementia.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric | 2004 |
The relationship between antipsychotic treatment and quality of life for patients with dementia living in residential and nursing home care facilities.
Topics: Aged; Antipsychotic Agents; Choice Behavior; Controlled Clinical Trials as Topic; Dementia; Dibenzot | 2004 |
Optimizing atypical antipsychotic treatment strategies in the elderly.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Controlled | 2004 |
Dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Donepezil; Galantamin | 2004 |
Do atypical antipsychotics cause stroke?
Topics: Antipsychotic Agents; Behavioral Symptoms; Benzodiazepines; Dementia; Humans; MEDLINE; Olanzapine; R | 2005 |
[Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia].
Topics: Antipsychotic Agents; Benzodiazepines; Dementia; Humans; Olanzapine; Randomized Controlled Trials as | 2005 |
Atypical antipsychotics for nursing home patients: a retrospective chart review.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Homes for the Aged; Humans; Medical Records; | 2005 |
[Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review].
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Dementia; Haloperidol; Humans; Olanzapine; Psycho | 2006 |
[Psychopharmacological treatment of behavioral and psychological symptoms in dementia].
Topics: Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; | 2006 |
Risperidone for the treatment of neuropsychiatric features in dementia.
Topics: Accidental Falls; Aged; Aged, 80 and over; Antipsychotic Agents; Cerebrovascular Disorders; Cognitio | 2006 |
Mortality in elderly dementia patients treated with risperidone.
Topics: Age Distribution; Age Factors; Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Clinical Trials | 2006 |
[Application of neuroleptics for dementia].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Behavioral Symptoms; Benzodiazepines; Dementia; Diben | 2007 |
The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dementia; Double-Blind Method; Fem | 2007 |
Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia.
Topics: Antipsychotic Agents; Benzodiazepines; Controlled Clinical Trials as Topic; Dementia; Dibenzothiazep | 2007 |
Treatment strategies for agitation and psychosis in dementia.
Topics: Aged; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Clozapine; | 1996 |
Managing the behavioral and psychological signs and symptoms of dementia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dementia; Humans; | 1997 |
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Adult; Age Factors; Aged; Algorithms; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clini | 1998 |
Conventional vs. newer antipsychotics in elderly patients.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia; Dibenzothiazepines; Dose-Re | 1999 |
Pharmacologic management of psychosis in dementia.
Topics: Aged; Antipsychotic Agents; Clozapine; Comorbidity; Delusions; Dementia; Hallucinations; Humans; Psy | 1999 |
Control of aggression and agitation in patients with dementia: efficacy and safety of risperidone.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Canada; Dementia; Dose-Response Relationship, Drug; D | 2000 |
Risperidone for control of agitation in dementia patients.
Topics: Aged; Clinical Trials as Topic; Dementia; Female; Humans; Risperidone | 2000 |
Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia.
Topics: Age Factors; Aggression; Animals; Antipsychotic Agents; Clinical Trials as Topic; Dementia; Dopamine | 2000 |
A risk-benefit assessment of risperidone for the treatment of behavioural and psychological symptoms in dementia.
Topics: Aged; Aging; Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; Humans; Risk A | 2000 |
Does risperidone have a place in the treatment of nonschizophrenic patients?
Topics: Bipolar Disorder; Clinical Trials as Topic; Dementia; Humans; Mental Disorders; Obsessive-Compulsive | 2001 |
Optimal dosing with risperidone: updated recommendations.
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Top | 2001 |
Movement disorders associated with neuroleptic treatment.
Topics: Age Factors; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; | 2001 |
Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Con | 2001 |
Long-term safety of risperidone.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Cholinesterase Inhibitors; Clinical Trials as To | 2001 |
Risperidone for the treatment of behavioral and psychological symptoms of dementia.
Topics: Aged; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Cognition | 2001 |
Broad therapeutic uses of atypical antipsychotic medications.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Child; Child Development Disorders, P | 2001 |
29 trials available for risperidone and Dementia
| Article | Year |
|---|---|
Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Basal Ganglia Diseases; Central Nervous System | 2013 |
Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; Female; Galantam | 2014 |
Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dementia; Dementia, Vascular; Fema | 2014 |
Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms.
Topics: Aged; Aged, 80 and over; Alleles; Antipsychotic Agents; Behavioral Symptoms; Citalopram; Dementia; F | 2010 |
A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia.
Topics: Aged, 80 and over; Citalopram; Dementia; Double-Blind Method; Female; Humans; Male; Psychiatric Stat | 2013 |
A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Double-Blind Method; Drug Administration Sche | 2003 |
Efficacy of risperidone for treating patients with behavioral and psychological symptoms of dementia.
Topics: Aged; Antipsychotic Agents; Dementia; Humans; Mental Disorders; Middle Aged; Prospective Studies; Ri | 2004 |
The effect of risperidone on nursing burden associated with caring for patients with dementia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Analysis of Variance; Antipsychotic Agents; Attitude | 2004 |
Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Dementia; Dementia, Vascular; Female; Hum | 2004 |
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cognition Disorders; Delusions; Demen | 2004 |
Open-label, observational study of the effects of risperidone on the behavioral and psychological symptoms of dementia and caregiver stress in the community setting.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Behavior; Caregivers; Community Health Services; | 2005 |
Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice.
Topics: Aged; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Delusions; Dementia; Female; Humans; | 2005 |
Evaluation of risperidone in the treatment of behavioral and psychological symptoms and sleep disturbances associated with dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; Female; Humans; Mal | 2005 |
[Changeover to risperidone after treatment with conventional low potency neuroleptics in dementia patients. An observation study during usage].
Topics: Aged; Aggression; Antipsychotic Agents; Behavior; Dementia; Dose-Response Relationship, Drug; Female | 2006 |
Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Anxiety Disorders; Cross-Over Studies; Dementia; Doub | 2006 |
Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Dibenzothiazepines; Female; Humans; Male; M | 2007 |
A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.
Topics: Aged, 80 and over; Antipsychotic Agents; Citalopram; Dementia; Double-Blind Method; Female; Hospital | 2007 |
Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study--the Bergen District Nursing Home Study (BEDNURS).
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dementia; Double-Blind Method; Femal | 2008 |
Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series.
Topics: Aged; Bipolar Disorder; Chronic Disease; Comorbidity; Dementia; Female; Hospitalization; Humans; Hyp | 1995 |
Nursing home research from industry's perspective.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Dementia; Dose-Response Relationship, Drug; Ethics, M | 1996 |
The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease.
Topics: Aged; Antipsychotic Agents; Dementia; Female; Humans; Male; Parkinson Disease; Pilot Projects; Psych | 1997 |
Clinical experience with risperidone, haloperidol, and thioridazine for dementia-associated behavioral disturbances.
Topics: Aged; Antipsychotic Agents; Chi-Square Distribution; Dementia; Haloperidol; Humans; Retrospective St | 1997 |
Risperidone for the treatment of behavioral disturbances in dementia: a case series.
Topics: Aged; Aged, 80 and over; Aggression; Antipsychotic Agents; Behavioral Symptoms; Delusions; Dementia; | 1998 |
Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases | 1999 |
A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.
Topics: Aged; Aged, 80 and over; Behavior; Dementia; Double-Blind Method; Female; Haloperidol; Humans; Male; | 1999 |
Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Dementia; Dementia, Vascular; Dose | 2000 |
Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly.
Topics: Administration, Oral; Aged; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dementi | 2001 |
Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Female; Humans; | 2002 |
A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances.
Topics: Aged; Analysis of Variance; Antipsychotic Agents; Carbamates; Cholinesterase Inhibitors; Dementia; D | 2002 |
106 other studies available for risperidone and Dementia
| Article | Year |
|---|---|
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Avoidance Learning; Benzoxazoles; Catalepsy; C | 2014 |
Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography.
Topics: Alzheimer Disease; Dementia; Electroencephalography; Galantamine; Humans; Neuropsychological Tests; | 2022 |
[Clinical use of psychotropic drugs: A look at antipsychotic drugs].
Topics: Aged; Antipsychotic Agents; Dementia; Drug-Related Side Effects and Adverse Reactions; Humans; Psych | 2023 |
Atypical Antipsychotics Augmentation in Patients with Depressive Disorder and Risk of Subsequent Dementia: A Nationwide Population-Based Cohort Study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Dementia; Depressive Disorder; Female | 2021 |
The Impact of Antipsychotic Drugs on Long-term Care, Nursing Home Admission, and Death in Dementia Patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Butyrophenones; Cohort Studies; Dementia; Female; Ger | 2018 |
Anticholinergic medicines use among older adults before and after initiating dementia medicines.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Australia; Cholinergic Antagonists; Cholinesterase In | 2019 |
Movement disorders in elderly users of risperidone and first generation antipsychotic agents: a Canadian population-based study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Canada; Dementia; Dibenzothiazepines | 2013 |
A biological basis for the sex bias of antipsychotic drugs adverse events.
Topics: Aged; Antipsychotic Agents; Cell Line; Cell Proliferation; Dementia; Dose-Response Relationship, Dru | 2013 |
Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antipsychotic Agents; Cohort Studies; Dementia; Female; Ha | 2014 |
Second-generation antipsychotic drug use in hospital inpatients with dementia: the impact of a safety warning on rates of prescribing.
Topics: Antipsychotic Agents; Dementia; England; Female; Humans; Inpatients; Male; Practice Patterns, Physic | 2015 |
Response to Bogaiksy's letter to the editor.
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; Female; Galantamine; Humans; Irritable Mo | 2014 |
Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial.
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; Female; Galantamine; Humans; Irritable Mo | 2014 |
Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Delirium; Dementia; Female; Haloperidol; | 2015 |
Don't use antipsychotics routinely to treat agitation and aggression in people with dementia.
Topics: Aggression; Antipsychotic Agents; Dementia; Drug Substitution; Humans; Interpersonal Relations; Long | 2014 |
Licensed indication for risperidone in dementia.
Topics: Aggression; Antipsychotic Agents; Dementia; Humans; Psychomotor Agitation; Risperidone | 2014 |
Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Drug Therapy, Combination; Female; Hospital | 2015 |
Prescribing of antipsychotics in UK primary care: a cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Bipolar Disorder; Child; Cohort St | 2014 |
An unsubstantiated conclusion.
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; Female; Galantamine; Humans; Irritable Mo | 2015 |
Dosage and duration of antipsychotic treatment in demented outpatients with agitation or psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Female; Humans; Male; Middle Aged; Outpatie | 2015 |
Treatment changes among older patients with dementia treated with antipsychotics.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dementia; Follow-Up Studies; Humans; | 2015 |
Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Dementia; | 2015 |
The use of antipsychotics among people treated with medications for dementia in residential aged care facilities.
Topics: Aged; Antipsychotic Agents; Assisted Living Facilities; Australia; Cross-Sectional Studies; Dementia | 2016 |
The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Databases, Factual; Dementia; Drug Prescriptions; Femal | 2016 |
Update on neuropsychiatric symptoms of dementia: antipsychotic use.
Topics: Aged; Aggression; Antipsychotic Agents; Aripiprazole; Dementia; Geriatric Psychiatry; Humans; Pipera | 2009 |
Older adult's acceptability ratings of treatments for verbal agitation in persons with dementia.
Topics: Aged; Aged, 80 and over; Aggression; Aging; Behavior Therapy; Dementia; Female; Humans; Male; Neurop | 2010 |
Antipsychotics and risk of cerebrovascular events in treatment of behavioural and psychological symptoms of dementia in Hong Kong: a hospital-based, retrospective, cohort study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cerebrovascular Disorders; Dementia; Female; Hong Kon | 2010 |
Effectiveness of safety warnings in atypical antipsychotic drugs: an interrupted time-series analysis in Spain.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Dose-Response Relationship, Drug; Drug and Na | 2009 |
Risperidone and dementia-related aggression: new indication. A last resort, no better than haloperidol.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Dementia; Drug Approval; Europe; France; | 2009 |
Delusional parasitosis as a presenting feature of dementia.
Topics: Aged; Animals; Antipsychotic Agents; Atrophy; Brain; Delusions; Dementia; Diagnosis, Differential; F | 2010 |
Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara.
Topics: Antipsychotic Agents; Behavioral Symptoms; Benzodiazepines; Cholinesterase Inhibitors; Dementia; Dib | 2010 |
Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia?
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Comorbidity; Dementi | 2010 |
Use and misuse of antipsychotic drugs in patients with dementia in Alzheimer special care units.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Antip | 2009 |
Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia.
Topics: Aged; Blood-Brain Barrier; Dementia; Domperidone; Dopamine Antagonists; Dopamine D2 Receptor Antagon | 2011 |
Risk of mortality among individual antipsychotics in patients with dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dementia; Dibenzothiazepines; Female | 2012 |
Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cause of Death; Comorbidity; Dementia; Dibenzothiazep | 2012 |
Recurrent delusional ideas due to left caudate head infarction, without dementia.
Topics: Aged; Antipsychotic Agents; Brain; Cerebral Infarction; Cerebrovascular Circulation; Delusions; Deme | 2012 |
Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Dementia; Dibenzothi | 2012 |
Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials.
Topics: Aged; Dementia; Dopamine Antagonists; Humans; Ischemic Attack, Transient; Randomized Controlled Tria | 2002 |
Antipsychotic drugs and diabetes.
Topics: Antipsychotic Agents; Causality; Dementia; Diabetes Mellitus; Humans; Obesity; Risperidone; Weight G | 2003 |
Use of atypical antipsychotic drugs in patients with dementia.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Comorbidity; Dementia; Dibenzothiazepines; H | 2003 |
[Treatment of behavioral disorders in dementia with risperidone in psychogeriatric outpatients].
Topics: Antipsychotic Agents; Clinical Trials as Topic; Dementia; Follow-Up Studies; Humans; Mental Disorder | 2003 |
Early Alzheimer's disease.
Topics: Antipsychotic Agents; Dementia; Humans; Risperidone; Stroke | 2004 |
Risperidone questioned as dementia first-line treatment.
Topics: Aged; Antipsychotic Agents; Dementia; Humans; Psychotic Disorders; Risperidone | 2004 |
Risperidone in the treatment of elderly patients with psychosis of Alzheimer's disease and related dementias.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Dementia; Double-Blind Method; Humans; Middle Aged; P | 2004 |
CSM warning on atypical psychotics and stroke may be detrimental for dementia.
Topics: Antipsychotic Agents; Benzodiazepines; Dementia; Humans; Olanzapine; Risk Factors; Risperidone; Stro | 2004 |
Atypical antipsychotics and risk of cerebrovascular accidents.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Comorbidity; Dementia; Female; Geriatri | 2004 |
Clinical effectiveness of atypical antipsychotics in dementia.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodi | 2004 |
[Neuroleptic malignant syndrome in users of risperidone].
Topics: Aged; Antipsychotic Agents; Dementia; Fatal Outcome; Female; Fever; Humans; Male; Neuroleptic Malign | 2004 |
Bradycardia at low doses of risperidone.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Bradycardia; Dementia; Geriatric Psychia | 2004 |
[Diphenhydramin-overdose: anticholinergic symptoms, EEG-findings in the course and drug treatment of a gerontopsychiatric patient].
Topics: Aged; Brain; Cholinergic Antagonists; Dementia; Depressive Disorder; Diphenhydramine; Drug Therapy, | 2004 |
[Neuroleptic malignant syndrome in users of risperidone].
Topics: Antipsychotic Agents; Dementia; Diagnosis, Differential; Humans; Neuroleptic Malignant Syndrome; Ris | 2005 |
[Neuroleptic malignant syndrome in users of risperidone].
Topics: Antipsychotic Agents; Dementia; Dose-Response Relationship, Drug; Humans; Neuroleptic Malignant Synd | 2005 |
[Neuroleptic malignant syndrome in users of risperidone].
Topics: Adult; Antipsychotic Agents; Dementia; Diagnosis, Differential; Humans; Male; Neuroleptic Malignant | 2005 |
[Neuroleptic malignant syndrome in users of risperidone].
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Dementia; Humans; Neuroleptic Malignant Syndrome; Ris | 2005 |
Cerebrovascular events after treatment of dementia patients with risperidone.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Female; Humans; Ischemic Attack, Transient; | 2004 |
[The recent controversy on the use of neuroleptics in the elderly with dementia].
Topics: Aged; Antipsychotic Agents; Dementia; Humans; Risperidone | 2005 |
[Neuroleptic malignant syndrome in users of risperidone].
Topics: Antipsychotic Agents; Dementia; Diagnosis, Differential; Humans; Neuroleptic Malignant Syndrome; Ris | 2005 |
[Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia].
Topics: Antipsychotic Agents; Benzodiazepines; Dementia; Humans; Olanzapine; Risk Factors; Risperidone; Stro | 2005 |
[Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia].
Topics: Antipsychotic Agents; Benzodiazepines; Dementia; Humans; Olanzapine; Risk Factors; Risperidone; Stro | 2005 |
Psychotropic medication and stroke outcome.
Topics: Age Factors; Aged; Animals; Behavior, Animal; Dementia; Humans; Male; Outcome Assessment, Health Car | 2005 |
FDA warns antipsychotic drugs may be risky for elderly.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dementia; Dibenzothiazepines; | 2005 |
Drugs used to relieve behavioral symptoms in people with dementia or an unacceptable chemical cosh? Argument.
Topics: Accidental Falls; Aged; Antipsychotic Agents; Benzodiazepines; Cerebrovascular Disorders; Cognition; | 2005 |
A case for judicious use of risperidone and olanzapine in behavioral and psychological symptoms of dementia (BPSD). Favour.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Geriatric Psychiatry; Humans; Ischemic Attack | 2005 |
Association between risperidone treatment and cerebrovascular adverse events in elderly patients with dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cerebrovascular Disorders; Dementia; Female; Humans; | 2005 |
The effect of risperidone on nursing burden associated with caring for patients with dementia.
Topics: Aged; Antipsychotic Agents; Dementia; Humans; Psychomotor Agitation; Risperidone; Workload | 2005 |
What happened to patients with behavioural and psychological symptoms of dementia (BPSD) after the Committee on Safety in Medicines (CSM) guidelines?
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Contraindications; Dementia; Drug Administration Sche | 2005 |
Psychotropic drug use in older people with mental illness with particular reference to antipsychotics: a systematic study of tolerability and use in different diagnostic groups.
Topics: Affective Disorders, Psychotic; Aged; Aged, 80 and over; Antidepressive Agents; Antipsychotic Agents | 2005 |
Population pharmacokinetics as a method to detect variable risperidone exposure in patients suffering from dementia with behavioral disturbances.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Behavioral Symptoms; Clinical Trials as Topic; Dement | 2005 |
Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cohort Studies; D | 2005 |
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cerebrovascular Disorders; Cohort St | 2005 |
Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Cross-Sectional Studie | 2005 |
Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued?
Topics: Administration, Oral; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cardiovascular | 2006 |
Anticholinergics in dementia and other confounding problems.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Benztropine; Dementia; Drug Resistance; Humans; Muscari | 2006 |
Hypothermia in a patient receiving risperidone and paroxetine.
Topics: Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Dementia; Female; Humans; Hypo | 2006 |
Duration of risperidone treatment for BPSD.
Topics: Aged; Aggression; Antipsychotic Agents; Dementia; Drug Administration Schedule; Female; Humans; Male | 2006 |
Survival among elderly Italian patients with dementia treated with atypical antipsychotics: observational study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Dementia; Female; Hu | 2006 |
Assertion that risperidone is superior to haloperidol for treatment of behavioural and psychological symptoms of dementia.
Topics: Antipsychotic Agents; Dementia; Haloperidol; Humans; Risperidone; Therapeutic Equivalency | 2007 |
Behavioral and psychological symptoms of dementia (BPSD) in elderly demented subjects: is the long lasting use of atypical antipsychotic drugs useful and safe?
Topics: Activities of Daily Living; Aged; Antipsychotic Agents; Benzodiazepines; Dementia; Female; Follow-Up | 2007 |
Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia.
Topics: Aged; Antipsychotic Agents; Dementia; Dose-Response Relationship, Drug; Double-Blind Method; Haloper | 2007 |
Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Behavioral Symptoms; Benzodiazepines; Dementia; Diben | 2007 |
Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications.
Topics: Administration, Oral; Aged; Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepine | 2007 |
Parkinsonism and tardive antecollis in frontotemporal dementia--increased sensitivity to newer antipsychotics?
Topics: Antipsychotic Agents; Benzodiazepines; Dementia; Dibenzothiazepines; Dystonia; Humans; Male; Middle | 2008 |
Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Anxiety; Benzodiazepines; Cross-Sectiona | 2008 |
[Atypical antipsychotics in elderly patients with dementia].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Dementia; Haloperidol; Humans; Metho | 2008 |
Neuroleptic malignant syndrome and catatonia in a patient with dementia.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catatonia; Chlorpromazine; Choline | 2008 |
Cortical response to exogenous visual stimulation during visual hallucinations.
Topics: Aged; Antipsychotic Agents; Dementia; Evoked Potentials, Visual; Hallucinations; Humans; Isoxazoles; | 1995 |
Risperidone for psychotic and behavioural symptoms in Lewy body dementia.
Topics: Aged; Antipsychotic Agents; Dementia; Female; Humans; Isoxazoles; Male; Piperidines; Risperidone | 1995 |
Risperidone for treating dementia-associated aggression.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Dementia; Dementia, Vascular; Female; Humans | 1995 |
Neuroleptic sensitivity to risperidone in Lewy body dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; Female; Humans; Iso | 1995 |
Risperidone and bullous pemphigoid.
Topics: Aged; Dementia; Female; Humans; Pemphigoid, Bullous; Risperidone | 1996 |
Adverse interaction of tacrine and haloperidol.
Topics: Aged; Dementia; Drug Interactions; Drug Therapy, Combination; Female; Haloperidol; Humans; Parkinson | 1996 |
The use of risperidone in severely demented patients with persistent vocalizations.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Dyskinesia, Drug-Induced; Female; Geriatric | 1997 |
Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Drug Resistance; Female; Geriatric Assessme | 1997 |
Risperidone in the treatment of delusions of infestation.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delusions; Dementia; Ectoparasitic Infestation | 1997 |
Combination of risperidone and donepezil in Lewy body dementia.
Topics: Aged; Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; Donepezil; Drug Therapy, Combinatio | 1998 |
Risperdal advertising in JAGS. Journal of the American Geriatrics Society.
Topics: Advertising; Aged; Antipsychotic Agents; Dementia; Drug Industry; Humans; Mental Disorders; Patient | 1999 |
Treatment of vocally disruptive behaviour of multifactorial aetiology.
Topics: Aged; Akathisia, Drug-Induced; Behavior Therapy; Dementia; Depression; Female; Homes for the Aged; H | 1999 |
Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Bipolar Disorder; Clozapine; Dementia; Drug Admin | 1999 |
Neuroleptics for behavioral symptoms of dementia.
Topics: Aggression; Antipsychotic Agents; Dementia; Evidence-Based Medicine; Humans; Mental Disorders; Resea | 2000 |
Neurologic side effects in neuroleptic-naïve patients treated with haloperidol or risperidone.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Dementia; Dose-Response Relationship, Drug; Halo | 2000 |
Risperidone and cognitive functioning in elderly schizophrenic patients.
Topics: Aged; Antipsychotic Agents; Dementia; Humans; Mental Status Schedule; Neuropsychological Tests; Risp | 2000 |
Side effects of antipsychotics in the elderly.
Topics: Age Factors; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Clozapine | 2000 |
Risperidone induced cytopenias.
Topics: Aged; Agranulocytosis; Dementia; Female; Follow-Up Studies; Humans; India; Risk Assessment; Risperid | 2000 |
Risperidone, tardive dyskinesia, and the elderly.
Topics: Age Factors; Aged; Antipsychotic Agents; Dementia; Dyskinesia, Drug-Induced; Follow-Up Studies; Huma | 2001 |
Donepezil management of schizophrenia with associated dementia.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Comorbidity; Dementia; Donepezil; Drug Therapy, Co | 2002 |
[Use of rispolept for psychotic symptoms in elderly patients with vascular psychoorganic syndrome].
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Female; Humans; Male; Middle Aged; Risperid | 2002 |